PTC THERAPEUTICS, INC. - 10-Q Filing

PTC Therapeutics reports Q3 2026 financial results including collaboration revenue from Novartis and updates to intangible asset valuations.

SEC EDGAR ·

Tickers: $PTCT

Read the full article at SEC EDGAR

More Regulatory news